beta blocker + aspirin + clopidogrel

This is a combination therapy consisting of a beta blocker, aspirin (acetylsalicylic acid), and clopidogrel. Each component has a distinct mechanism of action: - Beta blockers are antihypertensive agents that reduce heart rate, myocardial contractility, and blood pressure by antagonizing beta-adrenergic receptors. - Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, reducing thromboxane A2 production and thus platelet aggregation. - Clopidogrel is an antiplatelet agent in the thienopyridine class that irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing activation and aggregation. The combination is used primarily for secondary prevention in patients with acute coronary syndromes (ACS), after percutaneous coronary intervention (PCI) with stent placement, or for those at high risk of cardiovascular events. The dual antiplatelet therapy (DAPT) of aspirin plus clopidogrel reduces the risk of major adverse cardiovascular events compared to monotherapy but increases bleeding risk[1][5][6][8]. Beta blockers are added to further reduce cardiac workload and prevent arrhythmias or recurrent ischemia[6].